4S Trial: Difference between revisions
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==4S Trial== ===Objective=== To evaluate the effect of cholesterol lowering with simvastatin on mortality and morbidity in pati..." |
Rim Halaby (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To evaluate the effect of cholesterol lowering with simvastatin on mortality and morbidity in patients with [[coronary artery disease]] (CAD). | To evaluate the effect of cholesterol lowering with simvastatin on mortality and morbidity in patients with [[coronary artery disease]] (CAD). | ||
==Methods== | |||
The Scandinavian Simvastatin Survival Study (4S) enrolled 4444 patients with known CAD ([[angina pectoris]] or previous [[myocardial infarction]]) and serum cholesterol levels between 212 and 309 mg/dL. Patients were randomly assigned to either [[simvastatin]] (20 to 40 mg/day) or [[placebo]] and were followed-up for a median period of 5.4 years. | The Scandinavian Simvastatin Survival Study (4S) enrolled 4444 patients with known CAD ([[angina pectoris]] or previous [[myocardial infarction]]) and serum cholesterol levels between 212 and 309 mg/dL. Patients were randomly assigned to either [[simvastatin]] (20 to 40 mg/day) or [[placebo]] and were followed-up for a median period of 5.4 years. | ||
==Results== | |||
*Total cholesterol reduced by 25% | *Total cholesterol reduced by 25% | ||
*LDL-C levels reduced by 35% | *LDL-C levels reduced by 35% | ||
Line 17: | Line 16: | ||
*Significant reductions in major coronary events (19 versus 28 percent) | *Significant reductions in major coronary events (19 versus 28 percent) | ||
==Conclusion== | |||
The study showed that long-term treatment with simvastatin is safe and improves survival in CAD patients.<ref name="pmid7968073">{{cite journal |author= |title=Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) |journal=Lancet |volume=344 |issue=8934 |pages=1383–9 |year=1994 |month=November |pmid=7968073 |doi= |url=}}</ref> | The study showed that long-term treatment with simvastatin is safe and improves survival in CAD patients.<ref name="pmid7968073">{{cite journal |author= |title=Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) |journal=Lancet |volume=344 |issue=8934 |pages=1383–9 |year=1994 |month=November |pmid=7968073 |doi= |url=}}</ref> | ||
Line 26: | Line 25: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] |
Revision as of 23:27, 17 September 2013
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
4S Trial On the Web |
American Roentgen Ray Society Images of 4S Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To evaluate the effect of cholesterol lowering with simvastatin on mortality and morbidity in patients with coronary artery disease (CAD).
Methods
The Scandinavian Simvastatin Survival Study (4S) enrolled 4444 patients with known CAD (angina pectoris or previous myocardial infarction) and serum cholesterol levels between 212 and 309 mg/dL. Patients were randomly assigned to either simvastatin (20 to 40 mg/day) or placebo and were followed-up for a median period of 5.4 years.
Results
- Total cholesterol reduced by 25%
- LDL-C levels reduced by 35%
- Mean HDL-C improved by 8%
- Mortality rate was lower in the simvastatin group compared with that in the placebo group (8% vs 12%)
- Significant reductions in major coronary events (19 versus 28 percent)
Conclusion
The study showed that long-term treatment with simvastatin is safe and improves survival in CAD patients.[1]